中国药业2025，Vol.34Issue(14)：14-18,5.DOI:10.3969/j.issn.1006-4931.2025.14.004
某院神经内科重点监控药品临床应用调研
Investigation on Clinical Application of Key Monitoring Drugs in Department of Neurology of A Hospital
摘要
Abstract
Objective To promote the rational clinical use of key monitoring drugs in the Department of Neurology.Methods The medical records of patients who were discharged from the Department of Neurology and used key monitoring drugs in June 2023 were randomly selected from the hospital information system.According to the information of drug name,use mode,dosage and number of users,combined with Granada-Ⅱ classification,the drug-related problem(DRP)were classified and evaluated from the following three aspects:necessity(DRP1,DRP2),effectiveness(DRP3,DRP4)and safety(DRP5,DRP6).Results A total of 100 cases of patients were selected,and the classification of DRP only included DRP2,DRP4 and DRP5.There were 42 cases of DRP in 37 patients were occurred,of which DRP5,DRP2 and DRP4 accounted for 47.62%,35.71%and 16.67%,respectively.The incidence of DRPs in patients over 50-70 years old and over 70-90 years old were significantly higher than that in other age groups.The main incidence drug was Rabeprazole Sodium Enteric-coated Tablets(22 cases,52.38%).The main types of DRP were non-medication indications(15 cases,35.71%),high frequency of use(7 cases,16.67%),easy to cause adverse drug reactions(5 cases,11.90%),unreasonable solvent selection(2 cases,4.76%),excessive solvent volume(2 cases,4.76%),addition of other drugs to injections(6 cases,14.29%),and no etiological detection(5 cases,11.90%).Conclusion The key monitoring drug DRP in the Department of Neurology of the hospital is safety,followed by necessity and effectiveness.Pharmacists can use this to carry out intervention measures to improve the safety and effectiveness of drug use.关键词
神经内科/重点监控药品/Granada-Ⅱ分类法/药品相关问题/合理用药Key words
department of neurology/key monitoring drugs/Granada-Ⅱ classification/drug-related problem/rational drug use分类
医药卫生引用本文复制引用
曹芳,朱月皓,焦文斌,陈鹏,李阳,朱裕林,李杰..某院神经内科重点监控药品临床应用调研[J].中国药业,2025,34(14):14-18,5.基金项目
安徽省蚌埠市科技创新指导类项目[20210308]. （）
